Phase Space Research

Core Scientific

CORZ · Investment summary · as of 12 August 2026

Priced for an operating path the record does not support

Portfolio decision
No position
Price · 12 August 2026
$20.85
12-month target
$14.70 -29%
Expected return
-29.5%
Next decision point
23 October 2026Results expected (estimated)

Business type: Capital scale-up · scaling but economically observable

The business does not meet the quality standard for its economic type.

Investment view

At $20.85, CORZ requires a 71% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 26%.

The disagreement with the market is about the RATE at which contracted megawatts convert into revenue, not about the margin earned on them.

The value rests on an exit multiple of 9.8x, a terminal operating margin of 30% and a 11.0% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.

The strongest argument against this view: Permanent impairment of the equity through a counterparty credit event at one of two customers, transmitted through a capital structure that is levered against those same contracts.

Underwriting bridge

QuestionEvidence-based conclusion
What drives the business?The disagreement with the market is about the RATE at which contracted megawatts convert into revenue, not about the margin earned on them.
What do we forecast?Revenue growth of 26% demonstrated; a terminal operating margin of 30%; an exit multiple of 9.8x.
What does Street forecast?Not determined — no consensus estimates are joined to this record
Where do we differ?On revenue growth, the difference between what the price requires and what the business has demonstrated is -44.9 percentage points.
What is it worth?Twelve-month target $14.70, -29% from the struck price. Scenario-weighted expected return net of costs -29.5%.
Why now?Date not announced — no dated event that would resolve the disagreement is on file

What must go right

  1. By Q2 2027 (reported ~August 2027)The condition does not occur: Billable customer power capacity fails to reach 590MW by the Q2 2027 report — i.e. the CoreWeave buildout does not complete on the 'early 2027' schedule management stated in the 28 July 2026 investor presentation.Where it stands: Billable Customer Power Capacity (MW), the company's own defined term (deck slide 13)
  2. By Any two consecutive quarters from Q3 2026Colocation segment gross margin falls at or above 50% in two consecutive quarters.Where it stands: Colocation gross margin, filed segment note
  3. By Q4 2027 (reported ~February 2028)The condition does not occur: AMD initial delivery does not commence billing by the Q4 2027 report, against management's stated 'early 2027' initial delivery and 'full 530MW by the end of 2028'.Where it stands: Disclosed commencement of billing at Pecos TX or Auburn AL (the two sites guided to 1H 2027)

Catalysts and falsifiers

Date or windowEventThesis confirmed ifThesis weakened or refuted if
23 October 2026Next results (date estimated, not issuer-confirmed)Revenue and margin in line with, or above, the house pathA miss that moves the full-year path below the guided floor
Q2 2027 (reported ~August 2027)The near-term half of the revenue ramp, which is the least…Neither leg of the condition opposite is met at this dateBillable customer power capacity fails to reach 590MW by the Q2 2027 report
Any two consecutive quarters from Q3 2026The 30% terminal EBIT margin is built down from a 59% segment gross…Colocation segment gross margin falls at or above 50% in two consecutive quarters.Colocation segment gross margin falls below 50% in two consecutive quarters.
Q4 2027 (reported ~February 2028)The diversification thesis and the second half of the ramp.Neither leg of the condition opposite is met at this dateAMD initial delivery does not commence billing by the Q4 2027 report, against management's stated 'early 2027' initial…

Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.

Risk and sell discipline

Impairment case

Permanent impairment of the equity through a counterparty credit event at one of two customers, transmitted through a capital structure that is levered against those same contracts. The named cause is not 'demand for AI capacity falls'; it is that CORZ has converted a merchant business into a two-name credit exposure and financed it with $3.3bn of secured notes whose debt-service reserve is already funded from restricted cash. Mechanisms, each sourced: (1) CONCENTRATION — colocation is 83.2% of Q2 2026 revenue and essentially all of it is CoreWeave; the AMD/Neocloud leases signed 27 July 2026 add a second name but do not begin billing until 2027, so through the whole of the next twelve months the revenue base remains effectively single-name.

Estimated probability 25%, against the 18% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.

Fundamental invalidation

Falsifiable and fundamental — not one of them is a price condition.

Price-based risk trigger

A daily close below $15.64 triggers an immediate review of the thesis and pauses additional buying. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.

Upside sell discipline

On approach to the $14.70 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.

Investment criteria

CriteriaStatusInvestment meaning
QualityNot metIs the business worth owning under its declared economic type?
ValuationNot metIs the operating path required by today's price achievable?
LiquidityMetCan the intended position be built and exited in the right vehicle?
DownsideMetPermanent impairment of the equity through a counterparty credit event at one of two customers, transmitted through a capital structure that is levered against those same contracts.
MomentumNot determinedDoes price action support or complicate entry timing? Not established on the evidence on file.
CatalystNot determinedIs there a dated event that resolves the disagreement? Not established on the evidence on file.
ConsensusNot determinedIs the house-versus-Street disagreement identified and quantified? Not established on the evidence on file.

Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.

Bottom line

The gap between what today's price requires and what the business has demonstrated is -44.9 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: permanent impairment of the equity through a counterparty credit event at one of two customers, transmitted through a capital structure that is levered against those same contracts. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $15.64, which forces an immediate review.